New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT06770569
Summary
This is the first study in people testing a new cancer drug called HRS-3802. It aims to find a safe dose and see how the body handles the drug in 100 adults with advanced solid tumors that have not responded to standard treatments. Researchers will monitor for side effects and check if the drug helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact
-
GenesisCare North Shore (Oncology)
ACTIVE_NOT_RECRUITINGSaint Leonards, New South Wales, 2065, Australia
-
GenesisCare St Andrews
ACTIVE_NOT_RECRUITINGAdelaide, South Australia, 5000, Australia
-
John Flynn Private Hospital
ACTIVE_NOT_RECRUITINGTugun, Queensland, 4224, Australia
-
Macquarie University Hospital
ACTIVE_NOT_RECRUITINGSydney, New South Wales, 2109, Australia
-
Peninsula and South Eastern Haematology & Oncology Group
ACTIVE_NOT_RECRUITINGFrankston, Victoria, 3199, Australia
Conditions
Explore the condition pages connected to this study.